Apixaban in atrial fibrillation: From bleeding cows to 21st century medicinal chemistry

Stroke

Volumn 42, Issue 8, 2011, Pages 2376-2378

  Cucchiara, Brett L ^a   Kasner, Scott E ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

apixaban; atrial fibrillation; embolic stroke; oral anticoagulation; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CLOPIDOGREL; CREATININE; DABIGATRAN; DICOUMAROL; EDOXABAN; PLACEBO; RIVAROXABAN; WARFARIN; XIMELAGATRAN;

ARTICLE; BLEEDING; BLEEDING DISORDER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHEMICAL ENGINEERING; COST EFFECTIVENESS ANALYSIS; COW; CREATININE BLOOD LEVEL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; EMBOLISM; GENETIC VARIABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HISTORY OF MEDICINE; HUMAN; LIVER TOXICITY; MEDICINAL CHEMISTRY; MEDICINE; MELILOTUS OFFICINALIS; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; STROKE; STRUCTURE ACTIVITY RELATION; SYSTEMIC EMBOLISM; TRANSIENT ISCHEMIC ATTACK; X RAY CRYSTALLOGRAPHY;

ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; PYRAZOLES; PYRIDONES;

EID: 79961210694     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.619338     Document Type: Article

References (15)

1. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155-1166.
2. Nelson CW. Early dicumarol research and Mayo. Mayo Clin Proc. 1996; 71:220.
3. Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150:73-83.
4. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
5. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362: 1691-1698. (Pubitemid 37468318)
6. Pinto DJ, Smallheer JM, Cheney DL, Knabb RM, Wexler RR. Factor Xa inhibitors: next-generation antithrombotic agents. J Med Chem. 53:6243-6274.
7. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Newly identified events in the RE-LY trial. N Engl J Med. 363:1875-1876.
8. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
9. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867. (Pubitemid 351650486)
10. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
11. Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-1912.
12. Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364: 806-817.
13. Mant J, Hobbs FD, Fletcher K, Roalfe A, Fitzmaurice D, Lip GY, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503. (Pubitemid 47212371)
14. Mahaffey KM, Fox KAA; on behalf of the ROCKET AF Investigators. Rivaraoxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation [Abstract]. American Heart Association web site. Available at: http://static.smallworldlabs.com/ahascience/user-content/files/175/875/ 1758750075/3b57db985aca40242289179f089bccc4-rocket-af-pslides. pdf. Accessed June 4, 2011.
15. Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation (ARISTOTLE). ClinicalTrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/nct00412984. Accessed June 4, 2011.